{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T06:16:29Z","timestamp":1780553789275,"version":"3.54.1"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,13]],"date-time":"2024-10-13T00:00:00Z","timestamp":1728777600000},"content-version":"am","delay-in-days":317,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100015613","name":"Centre hospitalier r\u00e9gional universitaire de Lille","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015613","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.lungcan.2023.107393","type":"journal-article","created":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T06:26:30Z","timestamp":1696832790000},"page":"107393","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Characterization of 164 patients with NRAS mutated non-small cell lung cancer (NSCLC)"],"prefix":"10.1016","volume":"186","author":[{"given":"Agathe","family":"Dehem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Mazieres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Chour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Guisier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Boussageon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Girard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Moro-Sibilot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Cadranel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9rard","family":"Zalcman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Ricordel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Wislez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Munck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Poulet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9ment","family":"Gauvain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clotilde","family":"Descarpentries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Wasielewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis B.","family":"Cortot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3610-1316","authenticated-orcid":false,"given":"Simon","family":"Baldacci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.lungcan.2023.107393_b0005","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/ng1975","article-title":"High-throughput oncogene mutation profiling in human cancer","volume":"39","author":"Thomas","year":"2007","journal-title":"Nat. Genet."},{"issue":"7511","key":"10.1016\/j.lungcan.2023.107393_b0010","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature13385","article-title":"Comprehensive molecular profiling of lung adenocarcinoma","volume":"511","author":"Cancer Genome Atlas Research Network","year":"2014","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.lungcan.2023.107393_b0015","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S1470-2045(10)70087-5","article-title":"New driver mutations in non-small-cell lung cancer","volume":"12","author":"Pao","year":"2011","journal-title":"Lancet Oncol.."},{"issue":"7689","key":"10.1016\/j.lungcan.2023.107393_b0020","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nature25183","article-title":"The biology and management of non-small cell lung cancer","volume":"553","author":"Herbst","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.lungcan.2023.107393_b0025","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz167","article-title":"Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry","author":"Mazi\u00e8res","year":"2019","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"issue":"8","key":"10.1016\/j.lungcan.2023.107393_b0030","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41573-020-0068-6","article-title":"RAS-targeted therapies: is the undruggable drugged?","volume":"19","author":"Moore","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"issue":"14","key":"10.1016\/j.lungcan.2023.107393_b0035","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1158\/0008-5472.CAN-19-3682","article-title":"The frequency of Ras mutations in cancer","volume":"80","author":"Prior","year":"2020","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.lungcan.2023.107393_b0040","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nrc2109","article-title":"Hyperactive Ras in developmental disorders and cancer","volume":"7","author":"Schubbert","year":"2007","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.lungcan.2023.107393_b0045","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13045-021-01127-w","article-title":"Emerging strategies to target RAS signaling in human cancer therapy","volume":"14","author":"Chen","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"9","key":"10.1016\/j.lungcan.2023.107393_b0050","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1158\/1078-0432.CCR-12-3173","article-title":"Characteristics of lung cancers harboring NRAS mutations","volume":"19","author":"Ohashi","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.lungcan.2023.107393_b0055","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1146\/annurev.bi.62.070193.004223","article-title":"Function and regulation of Ras","volume":"62","author":"Lowy","year":"1993","journal-title":"Annu. Rev. Biochem."},{"issue":"1","key":"10.1016\/j.lungcan.2023.107393_b0060","first-page":"23","article-title":"GTPase activating proteins: critical regulators of intracellular signaling","volume":"1602","author":"Donovan","year":"2002","journal-title":"Biochim. Biophys. Acta BBA \u2013 Rev. Cancer."},{"issue":"3","key":"10.1016\/j.lungcan.2023.107393_b0065","first-page":"623","article-title":"Nras and Kras mutation in Japanese lung cancer patients: Genotyping analysis using Light Cycler","volume":"18","author":"Sasaki","year":"2007","journal-title":"Oncol. Rep."},{"issue":"2","key":"10.1016\/j.lungcan.2023.107393_b0070","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/sj.bjc.6601894","article-title":"The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website","volume":"91","author":"Bamford","year":"2004","journal-title":"Br. J. Cancer"},{"issue":"7216","key":"10.1016\/j.lungcan.2023.107393_b0075","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nature07423","article-title":"Somatic mutations affect key pathways in lung adenocarcinoma","volume":"455","author":"Ding","year":"2008","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.lungcan.2023.107393_b0080","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1093\/annonc\/mdr489","article-title":"Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice","volume":"22","author":"Sequist","year":"2011","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2023.107393_b0085","first-page":"405","article-title":"Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet. Med. Off. J. Am. Coll. Med. Genet."},{"issue":"9","key":"10.1016\/j.lungcan.2023.107393_b0090","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.3390\/cancers14092063","article-title":"KRAS mutations impact clinical outcome in metastatic non-small cell lung cancer","volume":"14","author":"Eklund","year":"2022","journal-title":"Cancers"},{"issue":"8","key":"10.1016\/j.lungcan.2023.107393_b0095","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1158\/1078-0432.CCR-20-4023","article-title":"Treatment outcomes and clinical characteristics of patients with KRAS-G12C\u2013mutant non-small cell lung cancer","volume":"27","author":"Arbour","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.lungcan.2023.107393_b0100","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.jtho.2019.01.020","article-title":"Characteristics and outcomes of patients with metastatic KRAS-mutant lung adenocarcinomas: the lung cancer mutation consortium experience","volume":"14","author":"El Osta","year":"2019","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2023.107393_b0105","article-title":"Clinical characteristics and outcomes in advanced KRAS-mutated NSCLC: A multicenter collaboration in Asia (ATORG-005)","volume":"3","author":"Lee","year":"2022","journal-title":"JTO Clin. Res. Rep."},{"issue":"6","key":"10.1016\/j.lungcan.2023.107393_b0110","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.3390\/jcm11061627","article-title":"Correlation of KRAS G12C mutation and high PD-L1 expression with clinical outcome in NSCLC patients treated with anti-PD1 immunotherapy","volume":"11","author":"Cefal\u00ec","year":"2022","journal-title":"J. Clin. Med."},{"issue":"3","key":"10.1016\/j.lungcan.2023.107393_b0115","article-title":"Outcomes of patients with advanced NSCLC From the Intergroupe Francophone de Canc\u00e9rologie Thoracique Biomarkers France Study by KRAS mutation subtypes","volume":"1","author":"Ruppert","year":"2020","journal-title":"JTO Clin. Res. Rep."},{"issue":"5","key":"10.1016\/j.lungcan.2023.107393_b0120","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.3390\/curroncol29050300","article-title":"HRAS Q61L mutation as a possible target for non-small cell lung cancer: case series and review of literature","volume":"29","author":"Mathiot","year":"2022","journal-title":"Curr. Oncol. Tor. Ont."},{"issue":"9","key":"10.1016\/j.lungcan.2023.107393_b0125","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.3390\/ijms23094517","article-title":"PD-L1 expression in non-small cell lung cancer specimens: association with clinicopathological factors and molecular alterations","volume":"23","author":"Mansour","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.lungcan.2023.107393_b0130","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s12253-018-0469-6","article-title":"The clinicopathological and molecular associations of PD-L1 expression in non-small cell lung cancer: analysis of a series of 10,005 cases tested with the 22C3 assay","volume":"26","author":"Evans","year":"2020","journal-title":"Pathol. Oncol. Res."},{"key":"10.1016\/j.lungcan.2023.107393_b0135","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.lungcan.2019.06.012","article-title":"Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non-small-cell lung cancer: The global, multicenter EXPRESS study","volume":"134","author":"Dietel","year":"2019","journal-title":"Lung Cancer Amst. Neth."},{"issue":"9","key":"10.1016\/j.lungcan.2023.107393_b0140","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/j.jtho.2021.03.028","article-title":"Prevalence and heterogeneity of PD-L1 expression by 22C3 assay in routine population-based and reflexive clinical testing in lung cancer","volume":"16","author":"Hwang","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2023.107393_b0145","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1093\/annonc\/mdy126","article-title":"Cytology cell blocks are suitable for immunohistochemical testing for PD-L1 in lung cancer","volume":"29","author":"Wang","year":"2018","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2023.107393_b0150","doi-asserted-by":"crossref","first-page":"429","DOI":"10.21037\/tlcr.2019.08.04","article-title":"The clinicopathological and prognostic significance of PD-L1 expression assessed by immunohistochemistry in lung cancer: a meta-analysis of 50 studies with 11,383 patients","volume":"8","author":"Li","year":"2019","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.lungcan.2023.107393_b0155","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.lungcan.2019.03.012","article-title":"A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape Project","volume":"131","author":"Kerr","year":"2019","journal-title":"Lung Cancer Amst. Neth."},{"issue":"5","key":"10.1016\/j.lungcan.2023.107393_b0160","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.annonc.2020.01.065","article-title":"Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas","volume":"31","author":"Schoenfeld","year":"2020","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.lungcan.2023.107393_b0165","article-title":"Landscape of biomarkers in non-small cell lung cancer using comprehensive genomic profiling and PD-L1 immunohistochemistry","volume":"27","author":"Huang","year":"2021","journal-title":"Pathol. Oncol. Res. POR"},{"issue":"21","key":"10.1016\/j.lungcan.2023.107393_b0170","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1002\/cncr.28306","article-title":"Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma","volume":"119","author":"Bucheit","year":"2013","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.lungcan.2023.107393_b0175","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1089\/thy.2014.0053","article-title":"NRAS codon 61 mutation is associated with distant metastasis in patients with follicular thyroid carcinoma","volume":"24","author":"Jang","year":"2014","journal-title":"Thyroid"},{"issue":"5","key":"10.1016\/j.lungcan.2023.107393_b0180","doi-asserted-by":"crossref","first-page":"R235","DOI":"10.1530\/ERC-15-0070","article-title":"RAS proto-oncogene in medullary thyroid carcinoma","volume":"22","author":"Moura","year":"2015","journal-title":"Endocr. Relat. Cancer"},{"issue":"12","key":"10.1016\/j.lungcan.2023.107393_b0185","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1158\/1535-7163.MCT-21-0201","article-title":"Characterization of KRAS mutation subtypes in non-small cell lung cancer","volume":"20","author":"Judd","year":"2021","journal-title":"Mol. Cancer Ther."},{"issue":"12","key":"10.1016\/j.lungcan.2023.107393_b0190","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1158\/2159-8290.CD-14-0729","article-title":"Mutation-specific RAS oncogenicity explains NRAS codon 61 selection in melanoma","volume":"4","author":"Burd","year":"2014","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.lungcan.2023.107393_b0195","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1158\/1078-0432.CCR-17-1841","article-title":"Effects of Co-occurring genomic alterations on outcomes in patients with KRAS-mutant non-small cell lung cancer","volume":"24","author":"Arbour","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.lungcan.2023.107393_b0200","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1158\/2159-8290.CD-14-1236","article-title":"Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities","volume":"5","author":"Skoulidis","year":"2015","journal-title":"Cancer Discov."},{"issue":"12","key":"10.1016\/j.lungcan.2023.107393_b0205","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1158\/1078-0432.CCR-16-2554","article-title":"Potential predictive value of TP53 and KRAS mutation status for response to PD-1 blockade immunotherapy in lung adenocarcinoma","volume":"23","author":"Dong","year":"2017","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"issue":"1","key":"10.1016\/j.lungcan.2023.107393_b0210","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.molonc.2012.09.002","article-title":"MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib","volume":"7","author":"Huang","year":"2013","journal-title":"Mol Oncol."},{"issue":"31","key":"10.1016\/j.lungcan.2023.107393_b0215","doi-asserted-by":"crossref","first-page":"E2127","DOI":"10.1073\/pnas.1203530109","article-title":"Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1","volume":"109","author":"Ohashi","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"12","key":"10.1016\/j.lungcan.2023.107393_b0220","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1158\/0008-5472.CAN-14-3167","article-title":"Acquired resistance to the mutant-selective EGFR inhibitor AZD9291 is associated with increased dependence on RAS signaling in preclinical models","volume":"75","author":"Eberlein","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.lungcan.2023.107393_b0225","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221079125","article-title":"Molecular landscape of osimertinib resistance in patients and patient-derived preclinical models","volume":"14","author":"Lim","year":"2022","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"8","key":"10.1016\/j.lungcan.2023.107393_b0230","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1158\/2159-8290.CD-21-0365","article-title":"Clinical acquired resistance to KRASG12C inhibition through a novel KRAS Switch-II pocket mutation and polyclonal alterations converging on RAS-MAPK reactivation","volume":"11","author":"Tanaka","year":"2021","journal-title":"Cancer Discov."},{"issue":"7886","key":"10.1016\/j.lungcan.2023.107393_b0235","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41586-021-04065-2","article-title":"Diverse alterations associated with resistance to KRAS(G12C) inhibition","volume":"599","author":"Zhao","year":"2021","journal-title":"Nature"},{"issue":"25","key":"10.1016\/j.lungcan.2023.107393_b0240","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","article-title":"Acquired resistance to KRASG12C inhibition in cancer","volume":"384","author":"Awad","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.lungcan.2023.107393_b0245","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/j.jtho.2021.07.009","article-title":"IMpower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous NSCLC","volume":"16","author":"Socinski","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2023.107393_b0250","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.jtho.2020.11.025","article-title":"Atezolizumab plus chemotherapy for first-line treatment of nonsquamous NSCLC: results from the randomized phase 3 IMpower132 trial","volume":"16","author":"Nishio","year":"2021","journal-title":"J Thorac. Oncol."},{"issue":"17","key":"10.1016\/j.lungcan.2023.107393_b0255","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced non-squamous non-small cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.lungcan.2023.107393_b0260","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.lungcan.2023.107393_b0265","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.annonc.2021.04.008","article-title":"Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189","volume":"32","author":"Rodr\u00edguez-Abreu","year":"2021","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2023.107393_b0270","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1470-2045(17)30180-8","article-title":"Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial","volume":"18","author":"Dummer","year":"2017","journal-title":"Lancet Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500223009315?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500223009315?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T13:05:36Z","timestamp":1759237536000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500223009315"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":54,"alternative-id":["S0169500223009315"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2023.107393","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization of 164 patients with NRAS mutated non-small cell lung cancer (NSCLC)","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2023.107393","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107393"}}